The Darbepoetin Alfa (Aranesp) Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Darbepoetin Alfa (Aranesp) Market:
https://www.thebusinessresearchcompany.com/report/darbepoetin-alfa-aranesp-global-market-report
According to The Business Research Company’s Darbepoetin Alfa (Aranesp) Global Market Report 2024, The darbepoetin alfa (aranesp) market size has grown strongly in recent years. It will grow from $5.56 billion in 2023 to $5.88 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to anemia treatment advancements, erythropoiesis-stimulating agents (esa) demand, biopharmaceutical innovation, clinical acceptance, improved patient outcomes.
The darbepoetin alfa (aranesp) market size is expected to see steady growth in the next few years. It will grow to $7.11 billion in 2028 at a compound annual growth rate (CAGR) of 4.8%. The growth in the forecast period can be attributed to healthcare reimbursement policies, increased awareness and education, healthcare infrastructure development, renal care demands, aging population. Major trends in the forecast period include global market penetration, digital health integration, personalized treatment approaches, adoption of biosimilars, long-acting formulations.
The increase in the prevalence of chronic diseases is expected to propel the growth of the darbepoetin alfa market going forward. A chronic disease is a form of illness that lasts three months or more and can deteriorate with time. Darbepoetin alfa is used to treat various chronic diseases, to reverse chemotherapy-induced anemia in cancer. For instance, in January 2023, according to the National Library of Medicine, a US-based agency, the number of people in the US aged 50 and older who have at least one chronic condition would increase by 99.5%, from 71.522 million in 2020 to 142.66 million by 2050. Therefore, an increase in the prevalence of chronic diseases is driving the growth of the darbepoetin alfa market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12171&type=smp
The darbepoetin alfa (aranesp) market covered in this report is segmented –
1) By Type: Epogen, Procrit, Aranesp, Other Types
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
3) By Application: Patients with Chronic Kidney Disease, Patients with Cancer, Other Applications
Product innovations are a key trend gaining popularity in the darbepoetin alfa market. Major companies operating in the darbepoetin alfa market are adopting new technologies to sustain their position in the market. For instance, in February 2023, GlaxoSmithKline. Ltd, a UK-based pharmaceutical and biotechnology company, introduced the US Food and Drug Administration (FDA), a US-based government agency that approved Jesduvroq (daprodustat). Daprodustat, recombinant human erythropoietin (rhEPO, darbepoetin alfa or epoetin alfa), is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor and is used once daily treatment of anemia brought on by chronic kidney disease (CKD) in people who have been on dialysis for at least four months.
The darbepoetin alfa (aranesp) market report table of contents includes:
1. Executive Summary
2.Darbepoetin Alfa (Aranesp) Market Characteristics
3.Darbepoetin Alfa (Aranesp) Market Trends And Strategies
4. Darbepoetin Alfa (Aranesp) Impact Of COVID-19
5. Darbepoetin Alfa (Aranesp) Market Size And Growth
6. Darbepoetin Alfa (Aranesp) Segmentation
7. Darbepoetin Alfa (Aranesp) Regional And Country Analysis
.
.
.
27. Darbepoetin Alfa (Aranesp) Competitive Landscape And Company Profiles
28. Darbepoetin Alfa (Aranesp) Key Mergers And Acquisitions
29. Darbepoetin Alfa (Aranesp) Future Outlook and Potential Analysis
TOP MAJOR PLAYERS:
- Johnson & Johnson,
- Amgen Inc.,
- Mylan N.V.,
- Teva Pharmaceutical Industries Ltd.,
- Serum Institute of India Pvt. Ltd.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
